PL1874278T3 - Kompozycje zawierające mikronizowany tanaproget - Google Patents
Kompozycje zawierające mikronizowany tanaprogetInfo
- Publication number
- PL1874278T3 PL1874278T3 PL06824718T PL06824718T PL1874278T3 PL 1874278 T3 PL1874278 T3 PL 1874278T3 PL 06824718 T PL06824718 T PL 06824718T PL 06824718 T PL06824718 T PL 06824718T PL 1874278 T3 PL1874278 T3 PL 1874278T3
- Authority
- PL
- Poland
- Prior art keywords
- compositions
- containing micronized
- micronized tanaproget
- hormone
- benign
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- PYVFWTPEBMRKSR-UHFFFAOYSA-N tanaproget Chemical compound CN1C(C#N)=CC=C1C1=CC=C(NC(=S)OC2(C)C)C2=C1 PYVFWTPEBMRKSR-UHFFFAOYSA-N 0.000 title abstract 2
- 229950001471 tanaproget Drugs 0.000 title abstract 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 abstract 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 abstract 1
- 201000009030 Carcinoma Diseases 0.000 abstract 1
- 229920002785 Croscarmellose sodium Polymers 0.000 abstract 1
- 201000009273 Endometriosis Diseases 0.000 abstract 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 abstract 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 abstract 1
- 206010046798 Uterine leiomyoma Diseases 0.000 abstract 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 abstract 1
- 208000009956 adenocarcinoma Diseases 0.000 abstract 1
- 230000000740 bleeding effect Effects 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 abstract 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 abstract 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 abstract 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 abstract 1
- 210000001072 colon Anatomy 0.000 abstract 1
- 229960001681 croscarmellose sodium Drugs 0.000 abstract 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 210000004696 endometrium Anatomy 0.000 abstract 1
- 230000037406 food intake Effects 0.000 abstract 1
- 235000012631 food intake Nutrition 0.000 abstract 1
- 229940088597 hormone Drugs 0.000 abstract 1
- 239000005556 hormone Substances 0.000 abstract 1
- 238000002657 hormone replacement therapy Methods 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 201000010260 leiomyoma Diseases 0.000 abstract 1
- 235000019359 magnesium stearate Nutrition 0.000 abstract 1
- 229940057948 magnesium stearate Drugs 0.000 abstract 1
- 230000003211 malignant effect Effects 0.000 abstract 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 1
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
- 230000002632 myometrial effect Effects 0.000 abstract 1
- 230000001613 neoplastic effect Effects 0.000 abstract 1
- 210000001672 ovary Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001817 pituitary effect Effects 0.000 abstract 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 abstract 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
- 229940069328 povidone Drugs 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 210000002307 prostate Anatomy 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pregnancy & Childbirth (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67559905P | 2005-04-28 | 2005-04-28 | |
| EP06824718A EP1874278B1 (en) | 2005-04-28 | 2006-04-26 | Compositions containing micronized tanaproget |
| PCT/US2006/016025 WO2007030153A2 (en) | 2005-04-28 | 2006-04-26 | Compositions containing micronized tanaproget |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1874278T3 true PL1874278T3 (pl) | 2009-12-31 |
Family
ID=37836301
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL06824718T PL1874278T3 (pl) | 2005-04-28 | 2006-04-26 | Kompozycje zawierające mikronizowany tanaproget |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8343965B2 (pl) |
| EP (1) | EP1874278B1 (pl) |
| JP (3) | JP5149161B2 (pl) |
| CN (1) | CN101166521A (pl) |
| AT (1) | ATE434434T1 (pl) |
| AU (1) | AU2006287925B2 (pl) |
| BR (1) | BRPI0610438A2 (pl) |
| CA (1) | CA2603817C (pl) |
| DE (1) | DE602006007453D1 (pl) |
| DK (1) | DK1874278T3 (pl) |
| ES (1) | ES2327783T3 (pl) |
| MX (1) | MX2007013468A (pl) |
| PL (1) | PL1874278T3 (pl) |
| WO (1) | WO2007030153A2 (pl) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602006012972D1 (de) * | 2005-04-28 | 2010-04-29 | Wyeth Corp | Mikronisierte tanaproget zusammensetzungen und verfahren zu ihrer herstellung |
| JP5149161B2 (ja) | 2005-04-28 | 2013-02-20 | ワイス・エルエルシー | ミクロ化タナプロゲットを含む組成物 |
| BRPI0610431A2 (pt) * | 2005-04-28 | 2012-10-23 | Wyeth Corp | composição farmacêutica, processo para preparar uma composição, cápsula, e, kit farmacêutico |
| MX2007013469A (es) * | 2005-04-28 | 2008-01-22 | Wyeth Corp | Forma ii polimorfa de tanaproget. |
| TW200716137A (en) | 2005-06-09 | 2007-05-01 | Wyeth Corp | Tanaproget compositions containing ethinyl estradiol |
| EA201070715A1 (ru) | 2007-12-20 | 2011-02-28 | Тева Вимен'С Хелс, Инк. | Режимы дозирования, фармацевтические композиции и упаковки для экстренной контрацепции |
| US8512745B2 (en) * | 2008-12-08 | 2013-08-20 | Laboratoire Hra Pharma | Ulipristal acetate tablets |
| US10071059B2 (en) | 2009-12-18 | 2018-09-11 | Frieslandcampina Nederland Holding B.V. | Co-processed tablet excipient composition its preparation and use |
| EP2545922A1 (en) * | 2011-07-12 | 2013-01-16 | PregLem S.A. | Treatment of excessive menstrual bleeding associated with uterine fibroids |
| JP2024530727A (ja) | 2021-08-25 | 2024-08-23 | ビーエーエスエフ ソシエタス・ヨーロピア | 直接打錠補助組成物 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK95093D0 (da) | 1993-08-20 | 1993-08-20 | Novo Nordisk As | Farmaceutisk formulering indeholdende et hormon |
| HUP0203332A3 (en) * | 1999-05-04 | 2004-12-28 | Wyeth Corp | Cyclothiocarbamate derivatives, their use as progesterone receptor modulators and pharmaceutical compositions containing them |
| UA73119C2 (en) | 2000-04-19 | 2005-06-15 | American Home Products Corpoir | Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors |
| US7056906B2 (en) * | 2001-09-21 | 2006-06-06 | Schering Corporation | Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women |
| CN1662241A (zh) | 2002-06-25 | 2005-08-31 | 惠氏公司 | 环硫代氨基甲酸酯衍生物在治疗与激素有关的病症中的用途 |
| CN1665510A (zh) | 2002-06-25 | 2005-09-07 | 惠氏公司 | 作为pr调节剂的环硫代氨基甲酸酯衍生物的衍生物和其用于治疗皮肤病的用途 |
| CA2505951A1 (en) | 2002-11-14 | 2004-05-27 | Shear/Kershman Laboratories, Inc | Oral testosterone delivery system with improved sustained release |
| US8404272B2 (en) | 2003-06-26 | 2013-03-26 | Poly-Med, Inc. | Fiber-reinforced composite rings for intravaginal controlled drug delivery |
| CA2563063C (en) | 2004-04-27 | 2014-06-03 | Wyeth | Purification of progesterone receptor modulators |
| CN1946716B (zh) | 2004-04-27 | 2011-12-21 | 惠氏公司 | 含有氰基吡咯的环状氨基甲酸酯和硫代氨基甲酸酯联芳基以及其制备方法 |
| US20060009428A1 (en) | 2004-07-07 | 2006-01-12 | Wyeth | Cyclic progestin regimens and kits |
| GT200500183A (es) | 2004-08-09 | 2006-04-10 | Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos | |
| GT200500185A (es) | 2004-08-09 | 2006-04-10 | Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos | |
| CA2575737C (en) | 2004-08-13 | 2013-09-24 | Wyeth | Tanaproget derivatives, metabolites, and uses thereof |
| CA2575803A1 (en) | 2004-08-20 | 2006-03-23 | Wyeth | Progesterone receptor structure |
| JP5149161B2 (ja) | 2005-04-28 | 2013-02-20 | ワイス・エルエルシー | ミクロ化タナプロゲットを含む組成物 |
| PE20061322A1 (es) | 2005-04-28 | 2006-12-28 | Wyeth Corp | Forma purificada de tanaproget |
| DE602006012972D1 (de) | 2005-04-28 | 2010-04-29 | Wyeth Corp | Mikronisierte tanaproget zusammensetzungen und verfahren zu ihrer herstellung |
| BRPI0610431A2 (pt) | 2005-04-28 | 2012-10-23 | Wyeth Corp | composição farmacêutica, processo para preparar uma composição, cápsula, e, kit farmacêutico |
| MX2007013469A (es) | 2005-04-28 | 2008-01-22 | Wyeth Corp | Forma ii polimorfa de tanaproget. |
| TW200716137A (en) | 2005-06-09 | 2007-05-01 | Wyeth Corp | Tanaproget compositions containing ethinyl estradiol |
-
2006
- 2006-04-26 JP JP2008509120A patent/JP5149161B2/ja not_active Expired - Fee Related
- 2006-04-26 CN CNA2006800142222A patent/CN101166521A/zh active Pending
- 2006-04-26 MX MX2007013468A patent/MX2007013468A/es active IP Right Grant
- 2006-04-26 BR BRPI0610438-0A patent/BRPI0610438A2/pt not_active IP Right Cessation
- 2006-04-26 WO PCT/US2006/016025 patent/WO2007030153A2/en not_active Ceased
- 2006-04-26 PL PL06824718T patent/PL1874278T3/pl unknown
- 2006-04-26 US US11/412,014 patent/US8343965B2/en not_active Expired - Fee Related
- 2006-04-26 DE DE602006007453T patent/DE602006007453D1/de not_active Expired - Lifetime
- 2006-04-26 CA CA2603817A patent/CA2603817C/en not_active Expired - Fee Related
- 2006-04-26 AT AT06824718T patent/ATE434434T1/de not_active IP Right Cessation
- 2006-04-26 ES ES06824718T patent/ES2327783T3/es not_active Expired - Lifetime
- 2006-04-26 EP EP06824718A patent/EP1874278B1/en not_active Expired - Lifetime
- 2006-04-26 DK DK06824718T patent/DK1874278T3/da active
- 2006-04-26 AU AU2006287925A patent/AU2006287925B2/en not_active Ceased
-
2012
- 2012-07-31 JP JP2012169806A patent/JP2012254999A/ja active Pending
- 2012-11-29 US US13/689,177 patent/US8791109B2/en not_active Expired - Fee Related
-
2014
- 2014-05-26 JP JP2014108568A patent/JP2014205683A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2007013468A (es) | 2008-01-21 |
| US8791109B2 (en) | 2014-07-29 |
| WO2007030153A3 (en) | 2007-08-09 |
| JP5149161B2 (ja) | 2013-02-20 |
| US8343965B2 (en) | 2013-01-01 |
| EP1874278A2 (en) | 2008-01-09 |
| EP1874278B1 (en) | 2009-06-24 |
| AU2006287925A1 (en) | 2007-03-15 |
| JP2012254999A (ja) | 2012-12-27 |
| ES2327783T3 (es) | 2009-11-03 |
| ATE434434T1 (de) | 2009-07-15 |
| CN101166521A (zh) | 2008-04-23 |
| CA2603817C (en) | 2013-03-19 |
| AU2006287925B2 (en) | 2012-03-01 |
| BRPI0610438A2 (pt) | 2012-10-23 |
| CA2603817A1 (en) | 2007-03-15 |
| JP2008539264A (ja) | 2008-11-13 |
| WO2007030153A2 (en) | 2007-03-15 |
| US20060247234A1 (en) | 2006-11-02 |
| US20130142838A1 (en) | 2013-06-06 |
| JP2014205683A (ja) | 2014-10-30 |
| DE602006007453D1 (de) | 2009-08-06 |
| DK1874278T3 (da) | 2009-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1110017T1 (el) | Μικρονισμενη ταναπρογετη και συνθεσεις που περιεχουν αυτην | |
| EP1896034B8 (en) | Micronized tanaproget compositions and methods of preparing the same | |
| TW200716621A (en) | Polymorph form II of tanaproget | |
| DK1874278T3 (da) | Sammensætninger indeholdende mikroniseret tanaproget | |
| JP2005511491A5 (pl) | ||
| PH12012501129A1 (en) | Neutralizing prolactin receptor antibodies and their therapeutic use | |
| WO2007016385A3 (en) | Use of substituted 5-amino-1h-pyrrole-2-carbonitrile derivatives as progesterone receptor modulators | |
| RU2016119135A (ru) | Производные пиразолопиримидона или пирролотриазона, способ их получения и их фармацевтические применения | |
| AU2003255820A8 (en) | Derivatives of 3-hydroxy-4-(cyclyl-alkylaminoalkyl)-5-phenyl-1h-pyrazole as antagonists of the gonadotropin releasing hormone (gnrh) for use in the treatment of sex hormone related conditions, such as prostatic of uterine cancer | |
| EA201491344A1 (ru) | Производные спироиндолина в качестве антагонистов рецептора гонадотропин-рилизинг гормона | |
| ATE515493T1 (de) | Mercaptophenylnaphthylmethan-derivate und deren herstellung | |
| JP2008539258A5 (pl) | ||
| NZ515353A (en) | Cyclothiocarbamate derivatives as progesterone receptor modulators | |
| CN105796567A (zh) | 新利司他固体分散体及其药物制剂 | |
| ATE275973T1 (de) | Empfängnisverhütende zusammensetzungen die progestagen und progesteronantagonisten enthalten | |
| CY1109919T1 (el) | Παραγωγα της ινδολης που ειναι χρησιμα σα ρυθμιστες του υποδοχεα της προγεστερονης | |
| MX2009009515A (es) | Cianopirrol sulfonamidas utiles para la modulacion del receptor de progesterona. | |
| EA201000097A1 (ru) | 8-бета-замещенные эстратриены в качестве селективно активных эстрогенов | |
| JP2008517871A5 (pl) | ||
| DOP2006000148A (es) | Moduladores no esteroides de receptores de progesterona | |
| RU2020138372A (ru) | Композиция для лечения одного или нескольких заболеваний, связанных с эстрогеном | |
| Cheng et al. | Apoptosis and Endometriosis | |
| JP2020114805A (ja) | エストロゲン受容体α阻害作用を有するエストロゲン受容体βパーシャルアゴニストを用いた、子宮内膜症、子宮腺筋症等の婦人科疾患の疼痛、及び／又は器質的病変の治療剤 | |
| Quan-xin et al. | Evaluation on Neoadjuvant Chemotherapy in Advanced Ovarian Carcinoma | |
| TH76512A (th) | ตัวคุมโปรเจสเตอโรน รีเซปเตอร์ที่ประกอบรวมด้วยอนุพันธ์ไพร์โรล-ออกซินโดล และการใช้สารนั้น |